Companies › Taiho Oncology
7 active drug programs in 19 registered trials: 9 Phase 2, 7 Phase 1, 3 Phase 3; Oncology, Hematology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cln-081 (TAS6417) Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation; Lung Cancer; Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations | May 2027 |
| Futibatinib (TAS-120) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Advanced Cholangiocarcinoma; Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Advanced/Metastatic Cancer; Biliary Tract Neoplasms … | Dec 2026 |
| Azacitidine (ASTX030) DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 2 | Myelodysplastic Syndromes | Nov 2027 |
| Cedazuridine Cytidine deaminase inhibitor | CDA | Phase 2 | Myelodysplastic Syndromes; Solid Tumor | Nov 2027 |
| Decitabine (ASTX727) DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 1 | Acute Myeloid Leukemia | Dec 2026 |
| ASTX660 IAP inhibitor | IAP | Phase 1 | Solid Tumors; Advanced Cancer | Dec 2027 |
| ARC-02 | – | Phase 1 | B-cell Non Hodgkin Lymphoma | Jan 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03767075 | Futibatinib (TAS-120) | Phase 2 | Advanced Solid Tumor | Oncology | Nov 2026 |
| NCT05727176 | Futibatinib (TAS-120) | Phase 2 | Advanced Cholangiocarcinoma | Oncology | Dec 2026 |
| NCT04953897 | Decitabine (ASTX727) | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT04953910 | Decitabine (ASTX727) | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT05082259 | ASTX660 | Phase 1 | Advanced Cancer | Oncology | Dec 2026 |
| NCT05945823 | Futibatinib (TAS-120) | Phase 2 | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer | Oncology | Jan 2027 |
| NCT03875287 | Cedazuridine | Phase 1 | Solid Tumor | Oncology | Mar 2027 |
| NCT06506955 | Futibatinib (TAS-120) | Phase 2 | Advanced/Metastatic Cancer | Oncology | Apr 2027 |
| NCT05973773 | Cln-081 (TAS6417) | Phase 3 | Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation | Oncology | May 2027 |
| NCT05615818 | Futibatinib (TAS-120) | Phase 3 | Biliary Tract Neoplasms | Oncology | Jun 2027 |
| NCT06263153 | Futibatinib (TAS-120) | Phase 2 | Bladder Urothelial Carcinoma | Oncology | Jul 2027 |
| NCT04256317 | Azacitidine (ASTX030) | Phase 2 | Myelodysplastic Syndromes | Hematology | Nov 2027 |
| NCT04256317 | Cedazuridine | Phase 2 | Myelodysplastic Syndromes | Hematology | Nov 2027 |
| NCT02503423 | ASTX660 | Phase 1 | Solid Tumors | Oncology | Dec 2027 |
| NCT06722183 | Futibatinib (TAS-120) | Phase 2 | Colorectal Cancer | Oncology | Mar 2028 |
| NCT05967689 | Cln-081 (TAS6417) | Phase 2 | Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations | Oncology | Aug 2028 |
| NCT04657081 | Decitabine (ASTX727) | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2028 |
| NCT07691606 | ARC-02 | Phase 1 | B-cell Non Hodgkin Lymphoma | Oncology | Jan 2029 |
| NCT07128199 | Cln-081 (TAS6417) | Phase 3 | Lung Cancer | Oncology | Oct 2029 |
Tyra Biosciences Johnson & Johnson (Janssen) AstraZeneca Exelixis QED Therapeutics, a BridgeBio company TransThera Sciences (Nanjing) Hutchmed Eisai EpiDestiny AbbVie
Abbisko Therapeutics Jiangsu Alphamab Biopharmaceuticals Dizal Pharmaceuticals Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.